Relmada Therapeutics Inc. (RLMD)
| Bid | 0.64 |
| Market Cap | 21.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -79.98M |
| EPS (ttm) | -2.65 |
| PE Ratio (ttm) | -0.24 |
| Forward PE | -0.47 |
| Analyst | Hold |
| Ask | 0.65 |
| Volume | 3,545,684 |
| Avg. Volume (20D) | 1,713,816 |
| Open | 0.62 |
| Previous Close | 0.69 |
| Day's Range | 0.54 - 0.67 |
| 52-Week Range | 0.24 - 4.47 |
| Beta | 0.41 |
About RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder ...
Analyst Forecast
According to 4 analyst ratings, the average rating for RLMD stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 56.25% from the latest price.
Stock Forecasts
3 weeks ago · seekingalpha.com
Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call TranscriptRelmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors, IR Sergio Traversa - CEO Maged Shenouda - CF...